None listed
Conditions
Interventions
None listed
Sponsors
Dongguk University Ilsan Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Adults between the ages of 19 and 80 2) Patients with erosive reflux esophagitis confirmed by gastroscopy 3) Patients who have repeatedly had nocturnal acid secretion symptoms within the previous 3 months 4) Patients who have improved symptoms with PPI or gastric acid secretion inhibitor 5) Those who can understand and follow instructions and participate in the clinical trial
Exclusion criteria
Exclusion criteria: 1) Those with swallowing disorder or diagnosed with esophageal motility disease 2) Those who have been diagnosed with peptic ulcer and gastric cancer by gastroscopy within 3 months 3) Patients with gastroesophageal reflux disease who are refractory to PPI treatment 4) Patients who have undergone previous total gastrectomy 5) Patients who have participated in other clinical trials within 30 days from the date of screening and are taking investigational drugs 6) Those who fall under the contraindications in the precautions for use of investigational drugs 7) Patients who are pregnant or plan to become pregnant 8) Others judged by the researcher to be unfit to participate in this test
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Intensity of nighttime acid secretion symptoms (heart-burn, epigastric soreness, acid regurgitation, etc.) [VAS score (0-10)] 2) Frequency of nocturnal gastric acid secretion symptoms 3) Frequency of awakening from sleep due to symptoms of nocturnal gastric acid secretion | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reactions and safety 1) Collect all symptoms such as headache, dizziness, upper abdominal discomfort and hospital visit records 2) Check the association between this adverse reaction and fexuprazan and omeprazole | — |
Countries
Korea, Republic of
Contacts
Public ContactYun Jeong Lim
Dongguk University Ilsan Hospital
Outcome results
None listed